Target intelligence / Profile preview

Anandamide membrane transporter (AMT)

Target
AMT
Molecular classification
Transporter
01

Overview

The anandamide membrane transporter (AMT), also known as the anandamide uptake transport system or endocannabinoid transporter (EMT), is a hypothesized membrane-associated transport system that facilitates the cellular reuptake of the endocannabinoid anandamide (N-arachidonoylethanolamine, AEA) from the extracellular space. This transport system plays a critical role in terminating endocannabinoid signaling by clearing AEA from synaptic and extracellular environments, delivering it intracellularly where it is subsequently degraded by fatty acid amide hydrolase (FAAH). Although its functional activity is well-characterized by saturable, temperature-dependent, and inhibitor-sensitive uptake, the exact molecular identity of a dedicated transmembrane AMT protein remains highly controversial and has not been cloned. Some evidence suggests that AEA uptake occurs via passive diffusion driven by an intracellular concentration gradient maintained by FAAH, or is facilitated by intracellular carriers such as fatty acid-binding proteins (FABPs) and FAAH-like anandamide transporter (FLAT). Despite the lack of a cloned molecular target, the AMT is considered a viable therapeutic target. Pharmacological inhibition of AMT using small molecules like AM404, VDM11, or UCM707 elevates extracellular anandamide levels, thereby enhancing cannabinoid receptor activation. This approach offers therapeutic potential for treating pain, inflammation, anxiety, and neurodegenerative diseases, potentially with fewer psychotropic side effects than direct cannabinoid receptor agonists.

Other names
Anandamide uptake transport systemAnandamide transporterEndocannabinoid transporterEMTAnandamide reuptake transporter
02

Mechanism of action

Anandamide uptake inhibition

03

Biological functions

Neurotransmitter transportSignal transduction terminationEndocannabinoid clearanceLipid transport
04

Disease associations

PainInflammationNeurodegenerative diseaseAnxiety disordersDepression
05

Safety considerations

Off-target effects due to lack of molecular target validationPotential for mild cannabinoid-like side effectsCognitive impairmentMotor coordination impairment
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

Anandamide levelsExtracellular endocannabinoid levels

Beyond the preview

Go deeper on Anandamide membrane transporter (AMT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anandamide membrane transporter (AMT).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call